west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "非霍奇金" 20 results
  • Effectiveness and Safety of Chemotherapy Regimens Represented by Pirarubicin versus Adriamycin Hydrochloride for Non-Hodgkin Lymphoma in Mainland China: A Meta-Analysis

    Objective To evaluate the effectiveness and safety of chemotherapy regimens represented by pirarubicin (THP) vs. adriamycin hydrochloride (ADM) for non-Hodgkin lymphoma (NHL) in mainland China. Methods The randomized controlled trials (RCTs) about THP vs. ADM for treating NHL were collected in the databases such as CNKI, CBM, VIP and WanFang Data, and the references of the included studies were also retrieved manually, with the retrieval time from January 1989 to September 2012. According to the inclusion and exclusion criteria, two reviewers independently screened articles, extracted data, and assessed the methodological quality of the included studies. Then meta-analysis was performed using RevMan 5.0 software. Results A total of 15 RCTs involving 1 659 patients were included. The results of meta-analysis showed that: a) As for the total effective rate, the CTOP (C: cyclophosphamide, T: pirarubicin, O: vincristine, P: prednison) regimen was superior to the CHOP (C: cyclophosphamide H: adriamycin hydrochloride, O: vincristine, P: prednison) regimen with a significant difference (OR=1.07, 95%CI 1.02 to 1.12, P=0.006); and b) As for the safety, there were significant differences between the two groups in the incidence of cardiac toxicity (OR=0.42, 95%CI 0.30 to 0.57, Plt;0.000 01), gastrointestinal tract response (OR=0.69, 95%CI 0.56 to 0.85, P=0.000 5) and liver damage (OR=0.69, 95%CI 0.48 to 1.00, P=0.05). But no significant differences were found between the two groups in the incidence of mye1osuppression: the decreased hemoglobin (OR=0.83, 95%CI 0.61 to 1.14, P=0.25), leucopenia (OR=0.85, 95%CI 0.68 to 1.07, P=0.17), and thrombocytopenia (OR=0.99, 95%CI 0.70 to 1.39, P=0.95). Conclusion Based on the domestic evidences at current and compared with CHOP regimen represented by ADM, CTOP regimen represented by THP for treating NHL shows a higher total effective rate and less side effects. However, more high quality, large sample and double blind RCTs are required to prove this conclusion for the quality and quantity limitation of the included studies.

    Release date: Export PDF Favorites Scan
  • Pharmacoeconomic Evaluation on Chemotherapy Combined with Rituximab for Non-Hodgkin’s Lymphoma: A Systematic Review

    Objective To systematically evaluate the pharmacoeconomic vaule of chemotherapy combined with rituximab for patients with non-Hodgkin’s lymphomas (NHL). Methods A systematic literature search of cost-effectiveness studies on rituximab treating NHL published from 1998 to 2012 was carried out in following databases: PubMed, ScienceDirect, Health Technology Assessment (HTA) and Cochrane Database of Systematic Reviews (CDSR). And the references of included studies were also retrieved manually. The studies were screened according to the pre-designed inclusion and exclusion criteria, and the incremental cost- effectiveness ratio (ICER) in comparison between chemotherapy plus rituximab and chemotherapy alone was systematically evaluated according to the literature evaluation index system. Results The average ICER of Rituximab treating NHL was 16 318/QALY, 17 688/QALY, and 22 461/QALY in the UK, Mainland Europe, and US, respectively. All the reported ICERs in the included studies were below the implemented country-specific thresholds. Conclusion Based on present foreign literature, the integrated therapy of chemotherapy and rituximab for NHL is supposed to be a better cost-effective therapy with ICER below the implemented country-specific thresholds.

    Release date: Export PDF Favorites Scan
  • Secondary Acute Myeloid Leukemia M6 after Treatment of Non-Hodgkin’s Lymphoma: A Report of One Case

    目的 增加对治疗相关性继发白血病的认识。 方法 报道非霍奇金淋巴瘤治疗后2年继发急性髓细胞白血病M6型1例,结合文献讨论治疗相关性白血病的发病机制、治疗、预后。 结果 1例73岁非霍奇金淋巴瘤患者接受R(Rituxmab,利妥昔单抗)-CHOP环磷酰胺+多柔比星+长春新碱+泼尼松方案规律化学治疗。治疗结束24+个月后,经骨髓涂片及细胞免疫分型诊断为急性髓细胞白血病M6型,染色体检查为:44~48,XY,del(5)(q12q33),-8,-10,der(12)t(4;12)(q11-q12;p13),其一般情况急剧恶化并死亡。 结论 治疗相关性白血病的发生可能与烷化剂等化疗药物使用和免疫受损等有关,利妥昔单抗导致第二肿瘤的发生暂时不能除外。治疗相关性白血病常伴有复杂染色体核型,其病情发展迅速,治疗效果差,生存期明显缩短。Objective To improve the understanding of secondary therapy-related leukemia. Methods The clinical data of one patient with non-Hodgkin lymphoma which transformed into acute myeloid leukemia M6 2 years after chemotherapy were studied. We discussed the pathogenesis, treatment and prognosis of therapy-related leukemia with literature review. Results A 73-year-old patient diagnosed to have non-Hodgkin’s lymphoma accepted R-CHOP chemotherapy.Two years after the treatment, the disease finally developed into acute myeloid leukemia M6 confirmed by cytogenetics, bone marrow morphology and flowcytometry analysis. The chromosome analysis demonstrated complex karyotypes as 44-48, XY, del (5) (q12q33), -8, -10, der (12) t (4; 12) (q11-q12; p13). His general status deteriorated rapidly and soon after the patient died. Conclusions Occurrence of therapy-related leukemia may be due to the administration of alkylating agents, topoisomerase inhibitors and damage of immune function. Therapy-related leukemia often occurs with complex karyotypes and progresses rapidly with poor treatment response.

    Release date: Export PDF Favorites Scan
  • Therapeutic Effect of Allogeneic Hematopoietic Stem Cell Transplantation on Relapsing Non-Hodgkin′s Lymphoma after Autologous Stem Cell Transplantation

    【摘要】 目的 探讨对自体造血干细胞移植(autologous hematopoietic stem cell transplantation,auto-HSCT)后复发的非霍奇金淋巴瘤患者再进行异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)治疗的临床疗效。 方法 收集2000年1月-2010年12月难治性恶性淋巴瘤采用auto-HSCT后复发患者11例,病程27个月~6.5年。所有患者在auto-HSCT前均为复发难治性病例,auto-HSCT后,完全缓解8例,部分缓解3例,自体移植后中位复发时间15个月,患者复发后采用异基因亲缘造血干细胞移植,人类白细胞抗原(human leukocyte antigen,HLA)全相合(6/6)6例,5/6相合3例,4/6相合2例;性别相同6例,性别不同5例。预处理方案为FBC方案,即氟达拉滨30 mg/m2 1~5 d,白消安12~14 mg/kg分4 d口服,环磷酰胺120 mg/kg分2 d使用。移植物均为外周血造血干细胞加骨髓。移植物抗宿主病(graft-versus-host disease,GVHD)的预防:HLA全相合采用环孢素+短程甲氨蝶呤+吗替麦考酚酯,不全相合采用抗胸腺细胞球蛋白+环孢素+短程甲氨蝶呤+吗替麦考酚酯。 结果 11例患者全部获得造血重建,急性GVHD发生6例(54.55%),其中Ⅰ度、Ⅱ度4例,Ⅲ度、Ⅳ度各1例;1例Ⅳ度GVHD因合并感染死亡,5例均得到有效控制;发生慢性GVHD 7例(63.64%),其中有2例急性GVHD转为慢性,4例局限型,3例广泛型。随访8个月~9年,有4例分别于移植后8、15、21、34个月疾病复发,另外6例仍生存。 结论 allo-HSCT对于auto-HSCT后复发的非霍奇金淋巴瘤患者仍是一种有效的挽救性治疗手段。【Abstract】 Objective To explore the clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on relapsing non-Hodgkin′s lymphoma after autologous stem cell transplantation (auto-HSCT). Methods The clinical data of 11 patients with recurrent non-Hodgkin′s lymphoma after auto-HSCT from January 2000 to December 2010 were collected, including nine males and 2 females with the median age of 39 years (13-48 years old), and the median duration of the disease was 3 years (27 months-6.5 years). All patients were relapsed or refractory cases. After auto-HSCT, complete remission was found in 8 and partial remission was in 3. The recurrence median time after auto-HSCT was 15 months. The patients underwent allo-HSCT after the recurrence of the disease. In the 11 patients, human leukocyte antigen (HLA) full matched (6/6) in 6, 5/6 matched in 3, and 4/6 matched in 2; the same gender in 6 and different gender in 5. FBC conditioning regimen: fludarabine 30 mg/m2 for 1-5 days, BU 12-14 mg/kg in 4 days of oral, CY 120 mg/kg in 2 days. Grafts are peripheral blood stem cells plus bone marrow. Prevention of graft-versus-host disease (GVHD): HLA full-matched by CsA+short-term MTX+MMF and mismatched by ATG+CsA+short-term MTX+MMF. Results All of the 11 patients received hematopoietic reconstruction, acute GVHD occurred in 6 cases (54.55%), including degree Ⅰ plus Ⅱ in 4, degree Ⅲ in 1 and degree Ⅳ in 1. One patient died of infection due to degree Ⅳ GVHD, and the rest had been effectively controlled. Chronic GVHD occurred in 7 patients (63.64%); limited type was in 4 in and extensive type was in 3. During the follow-up period of 8 months-9 years, 4 patients relapsed 8, 15, 21, and 34 months after transplantation, and the other 6 patients was still alive. Conclusion Allo-HSCT is effective on relapsing non-Hodgkin′s lymphoma after auto-HSCT.

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • Diagnosis and Treatment of Primary NonHodgkin’s Lymphoma of Kidney (Report of 5 Cases)

    目的:探讨肾脏原发性非霍奇金淋巴瘤(PNHL)的临床表现,诊治及预后特点。方法:总结我院自2000~2007年诊治的5例肾脏PNHL患者临床资料,5例患者术前均诊断为原发性肾癌。均行手术治疗,术后病理检查证实为非霍奇金淋巴瘤。 结果:拒绝化疗的患者于术后4个月死亡,一例73岁的高龄患者术后14个月死于化疗毒副反应,其余三例患者随访到现在,均无病生存。 结论:该病术前诊断困难,与原发性肾癌容易混淆,肾图对诊断该病或可提供一定参考价值。对该类肿瘤给予根治性切除,术后给予正确及时的个体化化疗可以获得较好的治疗效果,部分患者甚至可以长期无病生存。

    Release date:2016-08-26 02:21 Export PDF Favorites Scan
  • 原发性肺非霍奇金淋巴瘤一例报道并文献复习

    原发性肺非霍奇金淋巴瘤( primary pulmonary non-Hodgkin’s lymphoma, PPNHL) 是一种起源于肺内淋巴组织的罕见的恶性淋巴瘤。PPNHL 临床表现无特异性, 确诊大多依赖组织学依据, 故临床误诊率高, 误诊时间长。2009 年5 月我科确诊1 例, 诊断过程反复曲折, 现将该患者的临床表现、CT 及病理表现报告如下。

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
  • 眼内淋巴瘤五例

    Release date:2016-09-02 05:22 Export PDF Favorites Scan
  • The ocular features and misdiagnosis of intraocular non-Hodgkin's lymphoma

    Objective To observe the ocular features and analyze the cause of misdiagnosis of intraocular nonHodgkin's lymphoma (IONHL). Methods A retrospective study was performed in 6 patients and related literatures were reviewed. The age of those patients was 46 to 68 yrs with an average of 562 yrs. Four cases were female, two cases were male. Five patients were unilateral and one case was bilateral case. All patients were investigated by Goldmann tonometer, fundus fluorescein angiography (FFA) and ophthalmic Bscan. Pathological samples come from enucleation and vitrectomy, and were analyzed histologically and immunohistochemically. Results Ophthalmological signs of IONHL included decrease visual acuity, red eye, aqueous flare; keratic precipitates (Kp), vitreous opacity, retinal detachment and multiple whiteyellow retinal lesions of different sizes and fuzzy boundaries. IONHL patients were always misdiagnosed as diverse and nonspecific symptoms and signs, two cases were misdiagnosed as retinitis or chorioiditis, one case as intermediate uveitis, one case as secondary glaucoma in uveitis. The duration from onset of symptom and sign to a final diagnosis was from 6 months to 24 months with an average of 13.3 months. Conclusions The clinical manifestation of IONHL was diverse and non-specific,and this disease was unknown to lots of doctors and easily be misdiagnosed.

    Release date:2016-09-02 05:42 Export PDF Favorites Scan
  • 主要表现为眶尖综合征的非霍奇金淋巴瘤一例

    Release date:2016-09-07 02:34 Export PDF Favorites Scan
  • Clinical Analysis of Chronic Lymphocytic Leukemia Complicated with Non-Hodgkin’s Lymphoma

    目的 增加对慢性淋巴细胞白血病合并非霍奇金淋巴瘤临床病例的认识。 方法 通过报道2011年11月和2012年7月入住的2例确诊为慢性淋巴细胞白血病合并非霍奇金淋巴瘤患者的诊治过程,复习文献,讨论其发病机制、治疗及预后。 结果 该2例患者均予以化疗,其中1例浅表淋巴结明显缩小,骨髓涂片基本恢复正常,病情控制较好;另1例合并症多、病情恶化快、肿瘤化疗效果欠佳,最后因呼吸衰竭死亡。 结论 慢性淋巴细胞白血病合并非霍奇金淋巴瘤,治疗上应综合考虑患者年龄、ECOG评分、临床分期、预后指数等因素,原则上以治疗恶性程度更高的非霍奇金淋巴瘤为主,可根据慢性淋巴细胞白血病分期进行观察、随访或积极治疗。

    Release date: Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content